Shortage pharmaceuticals items; including, but not limited to blood products such as: carimune; oncological pharmaceuticals such as: vinblastine, novoseven and other relevant pharmaceuticals…
Ended Awarded
- Contract number
- HT001417F0139
- Awardee
-
The Compounding Center Inc. UEI J69ERCPB7369
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $300,000
Award facts
- Contract value 100% obligated
- $300,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 621111 Offices of Physicians (except Mental Health Specialists)
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 3 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20889, USA
Award details come from SAM.gov/FPDS.
About this award
This is a firm fixed price contract awarded by the Defense Health Agency (DHA) to The Compounding Center Inc., a minority-owned, self-certified small disadvantaged business. The $300,000 contract provides the DHA with a variety of pharmaceutical products, including blood products, oncology drugs, and other injectable, oral, and inhalation medications to address shortages impacting patient care at military and civilian treatment facilities.
The contract is structured as a Blanket Purchase Agreement (BPA) call, which allows the DHA to place expedited orders for customized medications and compounds over a 5-year ordering period. This streamlines the procurement of specialized drugs and shortage pharmaceuticals to support the agency's network of military hospitals and clinics. While some previous awards to The Compounding Center have utilized small business set-asides, this particular contract does not have a set-aside designation.
Description
Shortage pharmaceuticals items; including, but not limited to blood products such as: carimune; oncological pharmaceuticals such as: vinblastine, novoseven and other relevant pharmaceuticals products including injectables, orals and medicinal inhalations
Quick answers
Who was awarded contract HT001417F0139?
HT001417F0139 was awarded to The Compounding Center Inc. by Defense Health Agency (Department of Defense) on June 28, 2017.
How much is contract HT001417F0139 worth?
The government has obligated $300,000 on HT001417F0139.
Is contract HT001417F0139 an order under another contract?
Yes. HT001417F0139 is a BPA call under HT001415A0024, a blanket purchase agreement.
Was contract HT001417F0139 competed?
The extent of competition for HT001417F0139 was competed under sap. The government received 3 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award